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Abstract
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a complex multisystem 
illness that lacks effective therapy and a biomedical understanding of its causes. Despite a 
prevalence of approximately 0.2–0.4% and its high public health burden, and evidence that it 
has a heritable component, ME/CFS has not yet benefited from the advances in technology 
and analytical tools that have improved our understanding of many other complex diseases. 
Here we critically review existing evidence that genetic factors alter ME/CFS risk before 
concluding that most ME/CFS candidate gene associations are not replicated by the larger CFS 
cohort within UK Biobank. Multiple genome-wide association studies of this cohort also have 
not yielded consistently significant associations. Ahead of upcoming larger genome-wide 
association studies we discuss how these could generate new lines of enquiry into the DNA 
variants, genes and cell-types that are causally involved in ME/CFS disease. 
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Introduction
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a long-term, multisystem 
illness of unknown aetiology whose symptoms are highly debilitating (1). Large numbers of 
individuals are affected, estimated at 0.2% of the UK population (2), with the ratio of women 
to men diagnosed as high as 4-to-1 (2,3). This results in a substantial annual economic burden 
assessed at approximately £3.3 billion annually in the UK (https://meassociation.org.uk/wp-
content/uploads/2020Health-Counting-the-Cost-Sept-2017.pdf). Those diagnosed with 
ME/CFS experience diverse physical and cognitive symptoms but are most distinguished on 
the basis of post-exertional malaise, defined as a substantial worsening of symptoms following 
mental or physical activity that to healthy individuals would be minor, and which are not 
alleviated by resting (1, 4). The quality of life of people with ME/CFS is worse than for many 
other illnesses, including some cancers (5). 
Individuals with ME/CFS can be diagnosed after failing to recover fully following acute 
infection from viral and non-viral pathogens (6). In such cases it is assumed that infection 
initiates ME/CFS and thus contributes to its aetiology. Overall, however, the biological basis 
to ME/CFS is poorly understood, and currently there is little consensus among investigators on 
the molecular, cellular and genetic factors that alter risk of ME/CFS (7). Many biomolecular 
studies have sought biomarkers (factors such as RNAs, microRNAs, metabolites or proteins) 
whose abundance in blood, for example, accurately and reproducibly distinguishes ME/CFS 
cases from controls (8-14). Unfortunately, such a factor has yet to be identified in multiple 
independent studies.  If it were to be found then it would also need to accurately separate 
ME/CFS cases from people with unrelated diseases. 
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Multiple members of the same family can be diagnosed with ME/CFS (15, 16) which implies 
that inherited (i.e. genetic) factors might contribute to ME/CFS risk. However, ME/CFS 
diagnoses do not follow a predictable Mendelian pattern, which reveals that there is not one 
genetic variant that increases ME/CFS risk. Instead, ME/CFS is likely to be a complex 
multifactorial disorder whose genetic contributions are many and varied, as is known to be the 
case for example for many autoimmune diseases (17). These varied contributions will likely 
be of small individual effect, but together disrupt many genes and cellular or physiological 
processes. Each such variant is expected to contribute little to altered risk, implying that even 
in aggregate they cannot provide a reliable diagnosis. Genetics can objectively identify genes, 
molecules and cellular pathways that contribute to ME/CFS genetic risk, and these can then be 
targeted therapeutically. By contrast, molecular differences observed between patients and 
controls in other biomolecular studies could reflect the many secondary consequences of 
disease (e.g. a more sedentary lifestyle) rather than the disease’s primary cause. 
Here we first summarise ME/CFS diagnosis criteria before detailing the evidence for ME/CFS 
heritability and genetic risk factors. We then review the methodology, limitations and 
advantages of genome-wide association studies as applied to ME/CFS. This review is timely 
because it precedes the launch of DecodeME (www.decodeme.org.uk) and a similar study from 
the University of Oslo (www.ukbiobank.ac.uk/tag/cfs-me/). 
ME/CFS case definitions
Population genetics studies of disease rely on accurate case definition. For ME/CFS, however, 
no laboratory diagnostic test is currently approved. Rather, clinical diagnosis is made based on 
physical examination, case history and exclusion of other disorders. For research studies, 
investigators do not currently apply a single set of diagnostic criteria for ME/CFS or CFS cases. 
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Of the 20 existing sets of diagnostic criteria or case definitions (1), three are commonly applied 
in research and the use of a fourth (IOM/NAM) is expected in the future (Box 1). These 
different diagnostic criteria will select distinct, albeit overlapping, case cohorts and thus may 
not yield equivalent biomolecular findings.
Evidence that CFS risk is inherited
Various observations are consistent with genetic factors contributing to CFS risk for some 
individuals. Individuals with a CFS diagnosis (Fukuda or ICD-9 code 780.71 criteria) have a 
significant excess relatedness over the wider population for both close (first or second degree) 
and distant (third degree) relatives (16, 22). Of three studies that have estimated narrow-sense 
heritability (h2) using large cohorts, two reported non-zero h2-values that provide evidence for 
heritability of risk for CFS and, presumably, ME/CFS. An analysis of USA health insurance 
claimed a high narrow-sense heritability ( ) of CFS (23) whereas an analysis of UK ℎ2 = 0.48
Biobank individuals self-reporting a CFS diagnosis reported a less striking heritability (single 
nucleotide polymorphism- [SNP-] based approximate h2 = 0.08 with low confidence) (24, 
http://www.nealelab.is/uk-biobank). The third, a large twin-based study of CFS-like cases, 
produced an inconclusive result, with the 95% confidence interval of h2 including zero [0.03 
(0.00–0.65)] (25).
Mitochondrial and HLA genetics
Independent studies confirm that clinically proven mtDNA variants do not commonly explain 
ME/CFS (26-28). People with ME/CFS, however, appear more likely to carry mtDNA that 
lacks even mildly deleterious variants (28), a finding whose implications require further 
investigation.
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HLA proteins enable the immune system to differentiate self- from non-self cells such as 
foreign pathogens. Their genes exhibit extreme population polymorphism and certain HLA 
types are genetically predisposed to particular autoimmune diseases (29). Two independent 
HLA types tagged by HLA-C*07:04 or HLA-DQB1*03:03 were recently shown to be 
significantly associated with ME/CFS status (Canadian consensus criteria) (30). These alleles 
are each carried by ~10% of ME/CFS individuals and alter risk by approximately 1.5–2.0-fold. 
If these results are independently replicated then they indicate that genetic differences in the 
human immune system alter risk for ME/CFS.
Genome-Wide Association Study (GWAS)
A GWAS is ideal for discovering genetic causes of disease and new biology particularly when 
disease aetiology is unknown, as is the case for ME/CFS. This is not just because it is 
comprehensive but because its results are not influenced by pre-existing biological assumptions 
or hypotheses. GWAS was central to unexpected findings, for example of the role of glia, rather 
than neurons, in Alzheimer’s disease pathogenesis (31) and of components of the interleukin-
23 pathway in ankylosing spondylitis, psoriasis and psoriatic arthritis (32). Despite GWAS 
being expensive, sales of medications that have benefitted from this method already exceed its 
costs (32), and these are declining rapidly.  
In a GWAS approximately 0.5–2.5 million SNPs are genotyped and a stringent threshold of 
the test statistic (p-value) applied: < 5x10-8 for SNPs with minor allele frequency [MAF] > 5%, 
or < 1x10-8 for MAF ≥ 0.1% (33, 34). For CNVs the p-value threshold is less stringent because 
they are fewer in number, although no broad consensus on its value has yet been reached. To 
be adequately powered to find DNA variants of small effect, GWAS requires SNP genotype 
data from large numbers of cases and controls (preferably from many more controls than cases). 
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Case sample sizes of approximately 102 are well powered only to identify common (MAF 
~10%) variants with very strong effects (effect size ~1) whereas sample sizes of 104 are 
required to identify MAF~10% variants with weaker effects (~0.1) (32). This explains why 
GWAS often employ cohort sizes of ~104-106, and why when studies increase their cohort sizes 
they tend to discover larger numbers of lower-effect loci (35).  
ME/CFS genetics and UK Biobank 
UK Biobank is a 500,000-strong cohort that has been genotyped and exceptionally well 
phenotyped and hence is well suited to GWAS (36). One of the over 750 anthropometric and 
disease-related traits captured by UK Biobank is self-reported clinical diagnosis of CFS. This 
generated the largest cohort of people collected to date who have self-reported a clinical 
diagnosis (1,829 people). This number was approximately 0.45% of all UK Biobank 
participants and showed a marked female-bias (0.61% of females and 0.26% of males), as 
expected (37). As there is a likely ‘healthy volunteer’ selection bias (38) in UK Biobank these 
prevalence estimates are lower-bound values. It is unknown how many of these 1,829 
participants meet the ME/CFS criteria above, hence all results discussed below are preliminary 
and, as ever, require statistically robust replication. 
Five groups have performed a case-control GWAS on CFS cases in UK Biobank. 
Unfortunately, they reach no consensus and their results are far from being definitive. One 
study found no DNA variant to pass the p < 5x10-8 threshold (39). Another study reported 
results both partitioned and unpartitioned by sex (http://www.nealelab.is/uk-biobank) finding 
one variant associated with female CFS status and another with male or female CFS status 
(Table 1). Two other studies (24, 40) highlighted a single variant each (Table 1). The final 
study (https://pan.ukbb.broadinstitute.org/) found no variants associated with either the 
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Biobank CFS phenotype (Table 1), or the “phecode” definition of CFS (41). Consequently, 
despite these five studies analysing the same data set, not a single associated DNA variant was 
replicated by multiple analyses.  Two explanations of this lack of replication are likely. First, 
as alleles become rarer the likelihood increases that all people with the minor allele are placed 
among the cases just by chance. Two of the highlighted SNPs that are very rare in the 
population (MAF < 0.5%) are possible examples of this. Second, DNA sites that appear to have 
three or more alleles are usually excluded from analyses because they likely reflect technical 
genotyping artefacts (http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UK-Biobank-
Axiom-Array-Content-Summary-2014-1). One of the highlighted variants (rs148723539) is 
one such multi-allelic site (Table 1). 
The single remaining variant (rs7337312) is neither rare (MAF ≈ 0.5) nor multi-allelic and was 
identified in the female-only CFS GWAS by Neale et al. (http://www.nealelab.is/uk-biobank). 
This variant, together with adjacent significant variants that are in linkage disequilibrium, occur 
within a 51kb region containing the SLC25A15 gene (Figure 1). In most cases the gene affected 
by DNA variation is not the nearest (42) because of long-range genetic regulation (43). 
Nonetheless, because the rs7337312 variant predicts the amount of SLC25A15 mRNA 
transcribed from this gene in some tissue samples, SLC25A15 could be a causal gene of altered 
CFS risk. SLC25A15 encodes the Ornithine Transporter type 1 (ORNT1) protein that transports 
ornithine (as well as lysine and arginine) across the inner membrane of mitochondria to the 
mitochondrial matrix. Ornithine is an amino acid that plays a role in the urea cycle. A person 
with the rs7337312 CFS risk allele is expected to produce lower amounts of SLC25A15 mRNA 
resulting in reduced transport of ornithine into the mitochondrion and higher amounts of 
ornithine in blood. Yamano et al. (44) and Naviaux et al. (14), but not Armstrong et al. (45), 
report some evidence in support of this prediction. 
Page 8 of 23Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9
Using the same UK Biobank data, Aguirre et al. (46) tested for association with CNVs, finding 
two genes (TCOF1 and THUMPD2) to have a greater number of CNVs (either gains or losses) 
in UK Biobank CFS cases than in controls after applying a multiple-testing significance 
threshold of p < 3.1x10-6. Nevertheless, these results need to be treated with caution owing to 
CNV calling artefacts being prevalent at the low allele frequencies (<0.1%) used in the study.
Studies not using UK Biobank data
Smith et al. (47) undertook a GWAS on CFS (defined using Fukuda criteria) for very low 
numbers (40 cases and 40 non-fatigued control subjects) and reported 65 DNA variants as 
being associated at a non-standard highly permissive threshold of p < 10-3. When the well-
established threshold of p < 5x10-8 is applied, however, none remain significant. This is 
expected because, as discussed above, GWAS using this number of cases are only well 
powered to identify population frequent alleles with strong effects. 
A second GWAS also used similarly small cohort sizes (42 cases, defined using both Canadian 
and Fukuda criteria, and 38 controls) and reported 299 DNA variants as associated with 
ME/CFS status at p < 1x10-5 (48). The authors justified this permissive threshold as being an 
inclusion criterion of the GWAS Catalog (49). Nevertheless, p < 1x10-5 is used by the GWAS 
Catalog for reporting purposes only, and only for results from the overall (initial GWAS plus 
replication) population, when this study lacked a replication cohort. 15 variants were reported 
as genome-wide significant at p < 5x10-8 but these associations are not replicated in the UK 
Biobank cohort (Figure 2).
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Perez et al. (50) conducted a genetics study using 383 people who self-reported a clinical 
diagnosis of ME/CFS (Fukuda criteria). The study only considered DNA variants that disrupted 
genes despite >90% of variants associated with diseases or traits lying elsewhere in the genome 
(51). Using non-standard thresholds on variant frequency, the authors reported 5,693 DNA 
variants that are two-fold more (or less) frequent in cases versus controls. However, such case-
control allele frequency inequalities could have two technical, rather than biological, 
explanations. Firstly, errors stemming from poor DNA sample quality, incomplete DNA 
hybridisation to the genotyping array, or poorly performing array probes. Controlling for these 
errors imperfectly, or inconsistently between case and control genotypes, has led to retraction 
of publications reporting genetic associations (for example, (52)). Secondly, errors arising 
because confounding effects from the controls such as differences in genetic ancestry were not 
accounted for. 
Candidate gene studies
A recent review by leading human geneticists stated that: “initial efforts targeting variants 
within ‘candidate’ genes were plagued by inadequate power, unduly liberal thresholds for 
declaring significance and scant attention to sources of bias and confounding, resulting in 
overblown claims and failed replication” (53). Their confidence stems from knowledge that 
tens of thousands of associations have been identified by GWAS that subsequently are often 
replicated independently (49). An example of a candidate gene approach in ME/CFS research 
is a study of 9 DNA variants in the gene NR3C1 for 40 people with CFS and 42 controls (54). 
Four of these variants (rs1866388, rs2918419, rs860458 and rs6188) passed their statistical 
threshold for significance (p < 0.05). Nevertheless, none of these variants survive a Bonferroni 
multiple testing correction (p < 0.05/9 or p < 0.006) and none are replicated with the UK 
Biobank CFS cohort (24) (p = 0.96, 0.71, 0.71 and 0.97, respectively).
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To generalise this point, we again exploited the large cohort of self-reported CFS participants 
of UK Biobank. We tested for replication a large set of genetic findings reported in 16 CFS 
studies published between 2003 and 2015 that met the systematic review criteria of Wang et 
al. (55). Looking up associations between DNA variants (Table 1 of reference (55)) and CFS 
status in UK Biobank (24) for the 11 studies that had readily available SNP references yielded 
a p-value distribution between 0 and 1 (Figure 2a). Replication would require these p-values 
to be skewed towards small values. No such skew is observed (Figure 2a), consistent with 
random samples, hence these initial findings show no evidence of being replicated.
This conclusion is further substantiated from plotting the replication p-values for a further set 
of 77 DNA variants from Marshall-Gradisnik et al. (56), and 23 from Schlauch, et al. (48): 
these p-values also show a lack of skew towards small values (Figure 2b). 
Expected outcomes of a ME/CFS GWAS
GWAS are proposed to have “substantially improved our understanding of the mechanisms 
responsible for many rare and common diseases and driven development of novel preventative 
and therapeutic strategies” (53). This suggests that large GWAS on ME/CFS are overdue. 
Replicated results from such studies would have four important implications.
Firstly, it would catalyse the gain of much-needed insight into genes, cellular processes and 
tissues or cell types that causally alter risk for ME/CFS. When combined with functional 
genomics and other technologies (53), a well-designed GWAS can pinpoint multiple 
chromosomal locations containing DNA variants that change the activity of genes – in specific 
cells or tissues – that thereby alter a person’s risk of ME/CFS. If these genes are known to have 
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an activity in common – such as a mitochondrial or neurological or immunological function – 
then this common feature prioritises cellular processes and molecular mechanisms that could 
be causally involved in disease. Framing such causal hypotheses has been aided considerably 
by the knowledgebase of gene function, including activity levels, molecular mechanism and 
cellular function, which have been growing substantially and rapidly over recent years as a 
result of novel and higher throughput technologies. 
Secondly, a GWAS would enable detection of genetic signals that ME/CFS shares with other 
diseases or traits. Methods (e.g. (57)) that compare GWAS summary statistics for ME/CFS and 
other traits are available to calculate the genetic correlations between them. Genetic signals for 
ME/CFS could be shared with other diseases just as autoimmune diseases (for example, 
rheumatoid arthritis, type 1 diabetes, and autoimmune thyroid disease) share such signals and 
underlying mechanisms of disease (58).
Thirdly, a GWAS could aid stratification of ME/CFS sub-types. Despite their well-defined 
clinical diagnoses, complex diseases such as type 2 diabetes are caused by diverse molecular 
and cellular mechanisms (59) and this should also be expected of ME/CFS. Its underlying 
biological sub-types could eventually be detectable using methods that test for genetic effect 
heterogeneity (60). 
Lastly, discovery of genetic factors for ME/CFS risk might be expected to improve how this 
disorder is perceived by health professionals and by society at large.
Future perspective
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Genetics studies are the best way to understand the aetiology of ME/CFS, due to the causal 
nature of genetic associations. A large GWAS focused on discovering the biomolecular 
mechanisms of ME/CFS is urgently needed because no study on the genetics of ME/CFS yet 
has seen results repeated under replication. For an appropriately powered GWAS, at least 104 
participants are required, and an equal or greater number of controls. A strict p < 5x10-8 or 
1x10-8 statistical significance threshold must also be applied to reduce the numerous false 
positive associations seen from the meta-analyses presented here.
Although recruiting thousands of people with ME/CFS – particularly severely affected 
individuals who are house- or bed-bound – is a challenging task, it will be essential to perform 
a GWAS using their samples if we are to understand the mechanisms of the disease. With case 
criteria refined using genetic findings it may then be possible to begin stratifying the disease 
into distinct sub-types each with a different causal mechanism and potentially a specific 
treatment.
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Legends to Figures
Figure 1. 
A ME/CFS-associated GWAS locus on chromosome 13 (X-axis). Genome-wide significant 
SNPs from Neale et al. http://www.nealelab.is/uk-biobank are those lying above the horizontal 
dashed line. The location of the SLC25A15 gene is indicated below (exons are shown as vertical 
bars). The left-hand Y-axis reflects the statistical confidence (-log10 p-value) of the association 
between DNA variant and ME/CFS case status. The right-hand Y-axis (blue data curves) 
indicates the low extent of recombination within this locus. rs7337312 is highlighted as the 
reference variant (purple diamond). The degree of linkage disequilibrium of rs7337312 with 
neighbouring SNPs is indicated as r2 (right-hand legend).
Figure 2. 
Histograms of replication p-values for association of SNPs for CFS risk. These p-values were 
obtained from a UK Biobank CFS GWAS (24). Only variants tested in the UK Biobank were 
considered.
Panel a. Association p-values for SNPs identified in reference (59). 
Panel b. Association p-values for SNPs identified in references (60) and (52).
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Box 1. ME/CFS Case Inclusion/Exclusion Criteria.
1) The Fukuda Criteria developed in 1994 by the International Chronic Fatigue 
Syndrome Study Group (18). To be diagnosed with CFS, a person must display 
unexplained, persistent or relapsing chronic fatigue, as well at least four of eight 
additional symptoms. 
2) The Canadian Consensus Criteria (19). To be diagnosed, people with ME/CFS must 
exhibit a broad array of symptoms in specific combinations, namely:
i. cardinal symptoms of fatigue, post-exertional malaise or post-exertional 
fatigue, sleep dysfunction and pain (myalgia, often including headaches);
ii. two or more neurological and/or cognitive symptoms from a given list;
iii. at least one symptom from two of the following categories: autonomic, 
neuroendocrine and immune manifestations (with a list of relevant symptoms 
provided for each); and, 
iv. symptoms must have persisted for at least six months.
The authors also provided a list of co-morbidities, and another of illnesses that 
exclude the diagnosis of ME/CFS. These criteria seek to define patients with diverse 
symptoms, and have been proposed to preferentially select individuals with more 
severe symptoms (20).
3) International Consensus Criteria (21): This modifies the Canadian Consensus 
Criteria by revising criteria, adding others and removing both chronic fatigue as a 
criterion and the requirement of a six-month period prior to diagnosis. For 
diagnosis, a patient must display:
i. post-exertional neuroimmune exhaustion (broadly equivalent to post-exertional 
malaise);
ii. three neurological impairment symptoms    at least one each from three of four 
categories;
iii. three immune, gastro-intestinal or genitourinary symptoms    at least one from 
three of five categories; and,
iv. at least one energy production/transportation symptom.
4) USA Institute of Medicine (IOM, now called the National Academy of Medicine 
[NAM]) Criteria, developed for clinical not research purposes (1). Criteria were 
streamlined and focussed on core symptoms:
i. substantial reduction from pre-illness activity levels, evidence of post-
exertional malaise and unrefreshing sleep; and,
ii. cognitive impairment and/or orthostatic intolerance.
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Table
Table 1 - Summary of SNPs identified as significant in the UK Biobank CFS Cohort. Bold font indicates nominally significant p-values (< 5x10-
8). These five studies are cited in the Main Text.
DNA Variant Chromosome Nearby Gene Minor Allele 
Freq (GnomAD)
p  (Neale) 
female
p  (Neale) 
male
p  (Neale) 
both
p  (SAIGE) 
both
p (GeneAtlas) 
both
p  (Global 
Biobank Engine)
p  (Pan-UKBB)
rs7337312 13 SLC25A15 0.54 2.6x10-8 0.74 4.0x10-6 0.29 0.00017 9.3x10-6 2.1x10-4
rs150954845 10 P4HA1 0.00029 not reported not reported not reported 0.37 2.6x10-12 not reported not reported
rs148723539 10 EBF3 0.0093 9.7x10-7 6.1x10-4 2.3x10-9 0.29 not reported not reported 3.7x10-6
rs564809936 4 COX7B2 0.00016 not reported not reported not reported 3.8x10-8 not reported not reported 4.8x10-3
Abbreviations
CNV – Copy number variant
GWAS – Genome wide association study
HLA – Human Leukocyte Antigen
IOM/NAM – USA Institute of Medicine (now called the National Academy of Medicine [NAM])
MAF – minor allele frequency 
ME/CFS – Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
mt – mitochondrial 
ORNT1 – Ornithine Transporter type 1
SNP – single nucleotide polymorphism
Page 21 of 23 Human Molecular Genetics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
A ME/CFS-associated GWAS locus on chromosome 13 (X-axis). Genome-wide significant SNPs from Neale et 
al. http://www.nealelab.is/uk-biobank are those lying above the horizontal dashed line. The location of the 
SLC25A15 gene is indicated below (exons are shown as vertical bars). The left-hand Y-axis reflects the 
statistical confidence (-log10 p-value) of the association between DNA variant and ME/CFS case status. The 
right-hand Y-axis (blue data curves) indicates the low extent of recombination within this locus. rs7337312 
is highlighted as the reference variant (purple diamond). The degree of linkage disequilibrium of rs7337312 
with neighbouring SNPs is indicated as r2 (right-hand legend). 
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Histograms of replication p-values for association of SNPs for CFS risk. These p-values were obtained from a 
UK Biobank CFS GWAS (24). Only variants tested in the UK Biobank were considered.
Panel a. Association p-values for SNPs identified in reference (59). 
Panel b. Association p-values for SNPs identified in references (60) and (52). 
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